Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial
Julio Rosenstock, Julio Rosenstock, Daisuke Yabe, David A. Cox et autres
us, jp (code pays fourni par la source)